Co-beneldopa (including Madopar®) preparations re-classified as special containers
Update (30/01/2023) – Following representations from PSNC, the Department of Health of Social Care (DHSC) has re-determined the special container status of all Co-beneldopa capsules and tablets. In December 2022, PSNC advised that the special container rules apply to all branded or generically written prescriptions for Madopar® dispensed from December 2022 onwards (except for generically prescribed Co-beneldopa 12.5mg/50mg [...]
The post Co-beneldopa (including Madopar®) preparations re-classified as special containers appeared first on PSNC Website.
Recent Comments